Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498255 | 0.87 | FAAH (0.41) | PTPN1AGTR1AGTR2PLA2G2ATNF | |
| SCHEMBL6503025 | 0.84 | AGTR1 (0.46) | PTPN1AGTR1AGTR2 | |
| SCHEMBL6496755 | 0.83 | PDE3B (0.44) | PLA2G2ACYSLTR2CYSLTR1PDE3BPDE3A | |
| SCHEMBL6491512 | 0.83 | MCL1 (0.41) | PTPN1PLA2G2AMAPTTNFCYSLTR2 | |
| SCHEMBL6487030 | 0.82 | PDE3B (0.42) | PTPN1PLA2G2ACYSLTR2CYSLTR1PDE3B | |
| SCHEMBL6489517 | 0.81 | PDE3B (0.43) | PLA2G2ACYSLTR2CYSLTR1PDE3BPDE3A | |
| SCHEMBL6499832 | 0.81 | PLA2G2A (0.42) | PLA2G2AMAPTCYSLTR2CYSLTR1PDE3B | |
| SCHEMBL6486770 | 0.81 | MCL1 (0.40) | PLA2G2AMAPTTNFCYSLTR2CYSLTR1 | |
| SCHEMBL6502915 | 0.81 | SMN1; SMN2 (0.44) | PLA2G2AMAPTCYSLTR2CYSLTR1PDE3B | |
| SCHEMBL6501772 | 0.80 | PIK3C2B (0.47) | PLA2G2AMAPTCYSLTR2CYSLTR1PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | HSD17B2 824/4885PTPN1 2165/4885AGTR1 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.